Introduction {#s1}
============

Clathrin-Mediated Endocytosis (CME) enables cells to dynamically regulate the composition of the plasma membrane and mediate uptake of transmembrane cargo, such as ligand-bound receptors. This process is orchestrated by the clathrin Adaptor Protein two complex (AP2), which interacts with much of the endocytic machinery and functions during the earliest stages of CME ([@bib39]). Inactive, closed AP2 is initially recruited to the cytosolic face of the plasma membrane through its interaction with PhosphatidylInositol-4,5-bisPhosphate (PIP~2~) ([@bib12]; [@bib28]). At the plasma membrane, conformational rearrangement of AP2 to an active, open conformation is promoted by membrane-associated muniscin proteins ([@bib25]; [@bib27]; [@bib59]) ([Figure 1A](#fig1){ref-type="fig"}). Conversion of AP2 to the open conformation exposes a second binding site for PIP~2~ that stabilizes membrane engagement ([@bib32]), and also reveals binding sites for clathrin and membrane-embedded cargo ([@bib30]; [@bib34]). These interactions allow AP2 to function as the central regulatory hub of clathrin-coated vesicle formation ([@bib35]).

![NECAP PHear domain binds phosphorylated AP2 core.\
(**A**) AP2 comprises four subunits: alpha (α), beta (β), mu (μ), and sigma (σ). The complex also comprises a structured 'core' (dashed box) connected by flexible linkers to appendages on the alpha and beta subunits. Binding sites for AP2 substrates are indicated. PIP~2~, PhosphatidylInositol-4,5-bisPhosphate. (**B**) (Top) NECAP domain organization (numbers are for human NECAP2). (Center) Conservation scores of NECAP residues calculated using the ConSurf server ([@bib4]; [@bib8]). (Bottom) Truncation constructs used in this work. (**C**) Binding analysis of NECAP truncations compared to HaloTag control (-). HT, HaloTag; phosphoAP2, phosphorylated AP2 core. Representative image of three technical replicates. (**D**) Cryo-EM map of the phosphoAP2-NECAP complex (PDB 6OWO). Red: NECAP; Blue: AP2 mu; Gray: AP2 alpha, beta, sigma. See also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.](elife-50003-fig1){#fig1}

After opening, AP2 is phosphorylated on the mu subunit ([@bib13]; [@bib29]; [@bib44]), but the role of this mark remains poorly defined. Some data suggest that phosphorylation of AP2 enhances binding to PIP~2~ and cargo ([@bib18]; [@bib28]; [@bib49]). Additionally, mutation of the phosphorylated threonine (mu T156A) or addition of kinase inhibitors have been shown to inhibit transferrin uptake in tissue culture ([@bib41]), implying that phosphorylation promotes AP2 activity. Two kinases have been shown to phosphorylate AP2 (mu T156) in vitro: AP2-Associated Kinase (AAK1) ([@bib14]) and cyclin-G associated kinase (GAK) ([@bib60]). Curiously, studies involving these kinases suggest that phosphorylation may function in an inactivation pathway, as AAK1 appears to inhibit endocytosis using in vitro assays ([@bib14]), and GAK seems to function in vesicle uncoating ([@bib58]). Whether phosphorylation is an activating or inactivating mark, and whether it functions in multiple stages in the endocytic pathway remains to be determined.

While the pathways of clathrin adaptor activation have been well characterized both structurally and biochemically ([@bib12]; [@bib33]; [@bib34]; [@bib30]; [@bib48]; [@bib31]), it is unknown whether inactivation of AP2 is also a regulated process. Adaptor inactivation likely occurs throughout the endocytic cycle. High-resolution imaging reveals that many endocytic pits abort prematurely, presumably when a requirement for activation is unmet, such as an absence of PIP~2~, cargo, or muniscin ([@bib11]; [@bib32]). Abortive events could represent a mechanism to limit futile vesicle formation in the absence of cargo or prevent ectopic budding from off-target membranes lacking PIP~2~. Additionally, when adaptors are removed from vesicles prior to fusion with target organelles, they must also revert to the cytosolic, inactive state. Adaptor uncoating appears to require PIP~2~ phosphatase activity ([@bib15]; [@bib23]), but it is not known whether PIP~2~ hydrolysis is sufficient to uncoat AP2, as cytosol and ATP are required in vitro ([@bib22]). It remains to be determined whether adaptor inactivation occurs via stochastic disassembly of endocytic pits ([@bib16]), or if it is driven by regulated mechanisms, such as an endocytic checkpoint to ensure cargo incorporation ([@bib37]; [@bib47]).

We recently found that NECAP appears to act as a negative regulator of AP2 in vivo ([@bib6]). NECAP is a coat-associated protein that binds to the alpha appendage and beta linker regions of AP2 to facilitate endocytic accessory protein recruitment to sites of endocytosis ([@bib50]; [@bib51]; [@bib52]; [@bib53]). In *C. elegans*, loss of the muniscin, *fcho-1*, causes AP2 to dwell in an inactive, closed state ([@bib27]). Deletion of the gene encoding NECAP (*ncap-1*) in *fcho-1* mutants restores AP2 to an active, open and phosphorylated state, suggesting that NECAP counterbalances AP2 activation. Consistent with this model, NECAP binds open and phosphorylated AP2 complexes in vitro, however it is unclear how NECAP recognizes the open and phosphorylated states and whether NECAP can directly close these complexes.

Here, we determined cryo-EM structures of NECAP-AP2 complexes which show that NECAP clamps AP2 complexes into the closed, inactive conformation. This mechanism requires coincident binding of two domains of NECAP, one of which confers specificity for open complexes, and another that detects AP2 phosphorylation. Our structures are supported by in vitro biochemistry along with functional assays and unbiased genetic screens in *C. elegans*. Importantly, the site of AP2 phosphorylation is directly bound by NECAP, defining phosphorylation as a key step in the dynamic regulation of AP2 inactivation.

Results {#s2}
=======

Structural basis for recognition of phosphorylated AP2 by NECAP {#s2-1}
---------------------------------------------------------------

We previously demonstrated that NECAP binds to the phosphorylated AP2 core ([@bib6]). NECAP is a \~ 29 kDa, soluble protein composed of three domains: an N-terminal [P]{.ul}leckstrin [H]{.ul}omology with [ear]{.ul}-like function (NECAP~PHear~), a central [Ex]{.ul}tended region of conservation (NECAP~Ex~), and a C-terminal domain with low conservation (NECAP~Tail~) ([Figure 1B](#fig1){ref-type="fig"}) ([@bib52]; [@bib53]). While there are two paralogues of NECAP in vertebrates, we have previously shown that they function equivalently to bind phosphorylated and open AP2 complexes in vitro and rescue loss of NECAP in *C. elegans* ([@bib6]). In this work, we use human or mouse NECAP2 for all experiments because of their ease of purification and stability. To narrow down which domain of NECAP binds phosphorylated AP2, we performed in vitro pulldown assays using NECAP truncations and phosphorylated AP2 cores lacking appendages (phosphoAP2; rodent; boxed in [Figure 1A](#fig1){ref-type="fig"}). Our analysis showed that NECAP~PHear~ is necessary and sufficient to bind phosphorylated AP2 in vitro ([Figure 1C](#fig1){ref-type="fig"}).

Phosphorylation is thought to stabilize the open conformation of AP2 and we previously showed that NECAP can bind open AP2 that is not phosphorylated. To understand whether NECAP binds to the site of phosphorylation or a conformation induced by phosphorylation, we determined a \~ 3.2 Å cryo-EM structure of the phosphorylated AP2 core bound to full-length NECAP2 (mouse; [Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Table 1](#table1){ref-type="table"}). Globally, AP2 has adopted a conformation similar to the crystal structure of the closed complex (PDB 2VGL; [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}) ([@bib12]), which is inactive due to the occlusion of binding sites for cargo and the plasma membrane. We observe density for the entire AP2 core, with additional density contacting the mu subunit ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). Most of this additional density can be attributed to NECAP~PHear~, due to similarity with a solution NMR structure of the mouse NECAP1 PHear domain (PDB 1TQZ; [Figure 1---figure supplement 2B,C](#fig1s2){ref-type="fig"}) ([@bib52]). The remaining unassigned density at this interface extends from the amino terminus of residue 159 of mu, and can be attributed to the phosphorylated mu linker (amino acids 154--158, [Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}). The register leading up to this new density is based on a previous crystal structure (PDB 2VGL), and is confirmed by the positions of several landmark residues near T156 that fit the density well. A detailed schematic for building the critical T156 residue in our model is shown in [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}. Our structure is of sufficient quality to build a near-complete molecular model for the phosphoAP2-NECAP complex, which shows that residues in NECAP~PHear~ interact directly with the phosphorylated mu T156 (pT156; see Figure 3B below). These data show that the phosphorylated complex can exist in a closed conformation and suggest that the mechanism of NECAP binding to open complexes that are not phosphorylated must be fundamentally different.
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###### Cryo-EM data collection, refinement, and validation statistics.

  ---------------------------------------------------------------------------------------------------------
                                    pAP2-NECAP 'unclamped'\             pAP2-NECAP 'clamped'\
                                    PDB ID: 6OWO\                       PDB ID: 6OXL\
                                    EMDB ID: EMD-20215                  EMDB ID: EMD-20220
  --------------------------------- ----------------------------------- -----------------------------------
  **Data Collection**                                                   

  Microscope                        Talos Arctica                       Talos Arctica

  Camera                            K2 summit                           K2 summit

  Camera Mode                       Super-Resolution                    Counting

  Magnification                     36,000                              36,000

  Voltage (kV)                      200                                 200

  Total electron exposure (e-/Å2)   60                                  50

  Exposure rate (e-/pixel/sec)      6.67                                6.43

  Defocus Range (um)                0.6--2.5                            0.6--2.5

  Pixel Size (Å/pixel)              0.58                                1.16

  Micrographs collected (no.)       1092                                1497

  Micrographs used (no.)            944                                 1126

  **Reconstruction**                                                    

  3D Processing Package             Relion 3                            cryoSPARC v2

  Total Extracted picks (no.)       890,658                             717,231

  Refined particles (no.)           490,560                             388,962

  Final Particles (no.)             71,571                              324,922

  Symmetry                          C1                                  C1

  Resolution (global) (Å)           3.2                                 3.5

  FSC 0.143 (unmasked/masked)       4.1/3.2                             (4.2/3.5)

  Local resolution range (Å)        3.1--4.2                            3.2--6.1

  Map sharpening *B-*factor         −29                                 −160

  **Refinement**                                                        

  Model refinement package          Rosetta, phenix.real_space_refine   Rosetta, phenix.real_space_refine

  Model composition                                                     

  Nonhydrogen atoms                 14,280                              14,418

  Protein residues                  1785                                1814

  *B* factors (Å2)                                                      

  Protein residues                  62.53                               62.72

  R.m.s. deviations                                                     

  Bond Lengths (Å)                  0.009                               0.01

  Bond angles (°)                   1.182                               1.253

  **Validation**                                                        

  MolProbity (score/percentile)     1.4/97^th^                          1.75/87^th^

  Clashscore (score/percentile)     3.92/96^th^                         6.62/88^th^

  Poor rotamers (%)                 0.25                                0.06

  CaBLAM outliers (%)               1.34                                1.38

  Ramachandran plot                                                     

  Favored (%)                       96.57                               94.36

  Allowed (%)                       3.32                                5.64

  Disallowed (%)                    0.11                                0

  EMRinger score                    3.33                                3.05

  Map CC (*CCmask*)                 0.857                               0.815
  ---------------------------------------------------------------------------------------------------------

A genetic screen in *C. elegans* identifies mutations that disrupt the NECAP-AP2 interface {#s2-2}
------------------------------------------------------------------------------------------

Our structural data using vertebrate proteins imply that NECAP~PHear~ and its interaction with mu pT156 is central to the function of NECAP. To test this hypothesis, we turned to *C. elegans*, where we devised a genetic strategy to specifically isolate critical residues required for NECAP interaction with AP2, while avoiding mutations that destabilize the NECAP protein ([Figure 2A](#fig2){ref-type="fig"}). This screen was based on our previous screen for mutations that suppressed the morphological and fitness defects of *fcho-1* mutants and restored the active, open state of AP2. In the original screen, the predominant mutations identified were either gain-of-function mutations in AP2 subunits that destabilize the closed conformation ([@bib27]) or null mutations in the gene encoding NECAP, *ncap-1* ([@bib6]). To identify rare mutations that specifically disrupt the functional interface between AP2 and NECAP, we repeated the screen with a fluorescent tag on NECAP to enable secondary classification of suppressed animals based on fluorescent hallmarks ([Figure 2A](#fig2){ref-type="fig"}). Because gain of function mutations in AP2 result in NECAP recruitment to the nerve ring, a membranous tissue with a high concentration of AP2 ([@bib6]), we visually eliminated suppressed animals that had fluorescent nerve rings. We also eliminated suppressed animals that were no longer fluorescent, as these likely harbored null mutations in NECAP. We reasoned that the remaining animals, which suppressed *fcho-1* phenotypes without altering the fluorescent signal, might possess missense mutations that prevented NECAP from binding AP2. Worms that met these requirements were selected, and the genes encoding NECAP and AP2 were sequenced. We isolated mutations in NECAP~PHear~ and AP2 mu that were previously proposed to disrupt NECAP-AP2 interaction, as well as new potential interface mutations in the AP2 alpha and beta subunits ([Figure 2B and C](#fig2){ref-type="fig"}). Strikingly, the overwhelming majority of mutations (8 out of 13) isolated were in mu T156, suggesting that phosphorylation of this residue generates the substrate for NECAP activity.

![Genetic screen for NECAP-AP2 interface mutations.\
(**A**) Schematic of genetic screen to identify residues important for AP2-NECAP binding. FCHo mutants (*fcho-1*) exhibit growth defect and 'jowls' phenotype due to inactive AP2 (cartoon is anterior of worm). Fluorescent tag on NECAP (RFP:NECAP) enables visual categorization of suppressor mutations that restore AP2 activity. (**B**) Mutations identified in (**A**) mapped as red spheres onto the subunits of the closed AP2 crystal structure (2VGL) and our NECAP~PHear~ cryo-EM structure (PDB 6OWO). (**C**) Table of *C. elegans* mutations and their vertebrate equivalents referenced in this manuscript.](elife-50003-fig2){#fig2}

Coordination of phosphorylated AP2 by NECAP is required for inactivation {#s2-3}
------------------------------------------------------------------------

To understand how the mutated residues isolated in our screens disrupt NECAP function, we mapped the vertebrate equivalents onto our cryo-EM structure ([Figure 3A,B](#fig3){ref-type="fig"}). Mutations of T156 itself disable phosphorylation completely, and the two residues in NECAP~PHear~ (A32 and S87) lie within 10 Å of mu T156, which suggests that they disrupt coordination of the phosphate group and explains how they might break the AP2-NECAP interaction in vivo (throughout the text, all residue numbers are for vertebrate proteins, see [Figure 2C](#fig2){ref-type="fig"} for *C. elegans* equivalents). We also noticed that NECAP R112 forms electrostatic interactions with the T156 phosphorylation mark and may be required for binding ([Figure 3B](#fig3){ref-type="fig"}). To test the hypothesis that coordination of mu T156 phosphorylation is necessary for NECAP function, we introduced these mutations into recombinant vertebrate complexes and *C. elegans* strains and tested each using a panel of in vitro and in vivo assays. A bona fide interface mutant should reduce the function of NECAP in multiple assays, but not necessarily to the same degree in every assay. This is because each assay exhibits a different linear range, and point mutations may affect *C. elegans* and vertebrate proteins differently.

![Coordination of phosphorylated AP2 by NECAP is required for inactivation.\
(**A**) Cryo-EM of phosphoAP2-NECAP complex, boxed region shown in (**B**). (**B**) phosphoAP2-NECAP interface as a ribbon diagram inside a transparent rendering of the cryo-EM map with ball-and-stick representation of relevant NECAP side chains and mu pT156. Red: NECAP; Blue: AP2-mu. See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. (**C**) Binding analysis of interface mutants compared to HaloTag control (--). HT, HaloTag. Representative image of two technical replicates. (**D**) In the absence of NECAP (--), *fcho-1* mutants take about 4 days to proliferate and consume a bacterial food source (fitness defect = 0). Expression of NECAP (+) increases the number of days to about 8 (fitness defect = 1). Data for interface mutants were normalized to this fitness defect; n = 10 biological replicates. (**E**) (Left) In *fcho-1; apm-2 (E306K)* mutant worms, NECAP is recruited to the nerve ring. Interface mutants disrupt nerve ring recruitment, as quantified by in vivo confocal microscopy. (Right) Normalized RFP intensities plotted above representative confocal nerve ring images of ten biological replicates. (**D--E**) Error bars indicate mean ± SEM. Significance compared to NECAP (+); Student's t-test performed on raw data (**D**) or normalized data (**E**). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. (**F**) In vivo protease sensitivity assay to probe AP2 conformation in genetic backgrounds indicated. In the absence of NECAP (--), AP2 is protease sensitive (open). Expression of wild type NECAP (+) results in protease resistant AP2 (closed). All strains lack *fcho-1*.](elife-50003-fig3){#fig3}

As predicted, mutation of NECAP R112 disrupted binding in vitro, similar to either mutations in the mu linker (T156A) or NECAP~PHear~ (S87N) ([Figure 3C](#fig3){ref-type="fig"}). Consistent with the screen, the mutations suppressed the morphological and fitness defects of *fcho-1* mutants, as quantified by the number of days for a population to expand and consume a food source ([Figure 3D](#fig3){ref-type="fig"}). It is worth noting that mutation of R112 did not fully suppress the fitness defect, and thus would likely not have been isolated from our genetic screen. Additionally, chemical mutagenesis favors cytosine to thymine DNA transitions, thus disfavoring charge reversal of R112. Nonetheless, all three mutations reduced NECAP recruitment to the *C. elegans* nerve ring ([Figure 3E](#fig3){ref-type="fig"}) and resulted in accumulation of open AP2 complexes according to an in vivo protease sensitivity assay ([Figure 3F](#fig3){ref-type="fig"}). Together, our data show that NECAP~PHear~ binding to the phosphorylated threonine dictates AP2 inactivation.

While the AP2-NECAP~PHear~ interface is clearly important for inactivation, our cryo-EM structure does not explain why. NECAP~PHear~ only contacts the mu subunit of AP2, and there are no clashes when mu-NECAP~PHear~ is modeled as a rigid body into the crystal structure of open AP2 (PDB 2XA7; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Additionally, NECAP~PHear~ does not block cargo- or PIP~2~-binding sites and no obvious steric clashes would prevent AP2 from transitioning between open and closed states when bound to NECAP~PHear~ ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). One feature that might prevent NECAP~PHear~ binding to the open conformation is that mu T156 is packed against the beta subunit of AP2 in this structure ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}) ([@bib30]). This suggests that release and phosphorylation of the mu linker are important regulatory steps in NECAP recruitment. Nonetheless, while NECAP~PHear~ is required to inactivate AP2, binding of NECAP~PHear~ alone does not explain inactivation. Because mutations in NECAP~PHear~ do not disrupt binding to open, non-phosphorylated AP2 complexes ([@bib6]), we believe another domain of NECAP may contribute to its function.

Membrane mimetics stimulate opening of AP2 {#s2-4}
------------------------------------------

To understand how NECAP recognizes open AP2 in the absence of phosphorylation, we needed to control and measure the conformation of AP2 in vitro. We used structural data to engineer a protease site on AP2 that is preferentially cleaved in the open state ([@bib3]; [@bib27]; [@bib38]) ([Figure 4A](#fig4){ref-type="fig"}) and introduced a mutation in the mu subunit (mu E302K) that is known to promote the open conformation ([@bib27]). Despite this mutation, our AP2 complexes remained largely protease insensitive (i.e. closed) in the absence of other factors ([Figure 4B](#fig4){ref-type="fig"}). To produce open AP2, we turned to the observation that binding of AP2 to cargo is dramatically stimulated by the addition of long chain heparin ([@bib30]). Long anionic polymers are hypothesized to mimic negatively-charged PIP~2~-containing membranes. To test whether these types of negatively charged macromolecules could affect AP2 conformation, we included them in our protease sensitivity assay. Indeed, two anionic polymers, heparin and nucleic acids, generated protease-sensitive complexes, suggesting that they stimulated a conformational rearrangement of AP2 to the open state ([Figure 4B](#fig4){ref-type="fig"}). Importantly, the PIP~2~ mimetic, inositol hexakisphosphate (IP6), blocks the stimulatory effect of DNA on AP2, and is not sufficient to open the complex itself ([Figure 4B](#fig4){ref-type="fig"}), consistent with the model that open AP2 is stabilized by simultaneous engagement of multiple PIP~2~ binding sites by a contiguous polyanionic substrate.

![Membrane mimetics stimulate opening of AP2.\
(**A**) Schematic of protease sensitivity assay. Open AP2 exposes thrombin site on mu. K, mu E302K mutation. (**B**) Protease sensitivity of AP2 (mu E302K) in the presence of anionic polymers. Oligo, 60 nucleotide single-stranded DNA; plasmid, double-stranded DNA; RNA, total yeast RNA; IP6: inositol hexakisphosphate. (**C**) AP2 crystal structures (left, PDB 2VGL; right, PDB 2XA7) (**D**) (Top) Representative AP2 cryo-EM 2D class averages in the absence (left) or presence of oligo (47 nucleotide single-stranded DNA, right). (Bottom) Images from above overlaid with closed (left) or open (right) AP2 crystal structures. Blue: AP2 mu. The C-terminal domain of mu was omitted from the open crystal structure, as it is disordered in our cryo-EM class averages. (**E**) Proportion of AP2 particles assigned to either closed (gray) or open (blue) class averages. Data represents ten technical replicates (see definition of technical replicates for this assay in methods). See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. (**F**) Binding analysis of NECAP to AP2 (mu E302K) in the presence or absence of heparin. HT, HaloTag; K, mu E302K mutation. HaloTag control (-). Representative image of three technical replicates.](elife-50003-fig4){#fig4}

We confirmed that our protease-sensitivity assay was reporting structural changes using 2D and 3D classification of AP2 cryo-EM images. In the absence of a DNA oligo, both mu E302K and wild-type AP2 adopted a conformation that matches the crystal structure of the closed complex (PDB 2VGL; [Figure 4C--4E](#fig4){ref-type="fig"}). In the presence of an anionic membrane mimetic (47 nucleotide DNA),\~60% of wild type and more than 90% of AP2 (mu E302K) particles were open ([Figure 4C--4E](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Similar values are calculated when 3D classification is used ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). On the basis of these results we refer to AP2 (mu E302K) in the presence of anionic polymer as 'open AP2' in our experiments. In addition, this cryo-EM data suggests that the membrane itself affects the conformational equilibrium of AP2 and demonstrates that we can control the conformation of AP2 in vitro using a defined chemical substrate. Using our method to generate open AP2, we confirmed that NECAP bound these complexes in the absence of phosphorylation ([Figure 4F](#fig4){ref-type="fig"}).

NECAP~Ex~ recognizes membrane-activated AP2 {#s2-5}
-------------------------------------------

To identify the domain of NECAP that engages open AP2, we tested NECAP truncations ([Figure 1B](#fig1){ref-type="fig"}) and found that NECAP~Ex~ was necessary and sufficient for binding ([Figure 5A](#fig5){ref-type="fig"}). This supports previous data that binding of NECAP~PHear~ to AP2 in rat brain lysate is enhanced by the presence of NECAP~Ex~ ([@bib53]) and explains why NECAP~PHear~ mutants retain this binding ([@bib6]). Because the open state of AP2 precedes phosphorylation ([@bib13]; [@bib27]), we hypothesize NECAP~Ex~ may form an initial priming interaction with open AP2 prior to phosphorylation.

![NECAP~Ex~ recognizes membrane-activated AP2.\
(**A**) Binding analysis of NECAP truncations to AP2 (mu E302K) in the presence of heparin. HaloTag control (-). Representative image of two technical replicates. (**B**) Cryo-EM density of the phosphorylated AP2 (mu E302K)-NECAP complex in the presence of oligo (PDB 6OXL, 47 nucleotide single-stranded DNA, five molar excess). See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}.](elife-50003-fig5){#fig5}

To visualize NECAP bound to an activated, phosphorylated AP2 complex, we determined a \~ 3.5 Å structure of phosphorylated AP2 (mu E302K) bound to full-length NECAP2 in the presence of an anionic polymer (DNA) ([Figure 5B](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}, [Table 1](#table1){ref-type="table"}). In contrast to other AP2 (mu E302K) complexes incubated with DNA, ([Figure 4B and E](#fig4){ref-type="fig"}), AP2 was not open, but was in a closed, inactive conformation. As in our previous phosphoAP2-NECAP structure, NECAP~PHear~ was bound to the mu subunit, coordinating pT156. However, in this new structure we observed additional density contacting the beta subunit ([Figure 5B](#fig5){ref-type="fig"}). Comparing isosurface threshold levels of the unsharpened, refined map clearly shows that this density is contiguous and extends from the C-terminus of NECAP~PHear~ ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), suggesting it represents NECAP~Ex~. Because we cannot assign a definitive sequence register to the NECAP~Ex~ density in this structure, we model the most ordered region as a poly-alanine peptide. We believe this structure may represent a post-open, inactive conformation of the AP2 complex, corresponding to phospho-AP2 simultaneously bound by NECAP and partially engaged with the membrane via the PIP~2~ pocket on the alpha subunit. We refer to this structure as 'clamped' phosphoAP2-NECAP.

While NECAP~Ex~ appears to make extensive contact with the beta subunit of AP2 in this structure, the differences in AP2 conformation that might account for the appearance of the NECAP~Ex~ binding site are subtle (relative to that lacking DNA, [Figure 1D](#fig1){ref-type="fig"}, which we refer to as 'unclamped' phosphoAP2-NECAP). The region with the greatest structural changes is the alpha-beta interface, with several helices in the C-terminus of alpha shifting \~1--3 Å ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Additionally, an alpha helix in beta that is part of the Ex domain binding site appears to partially melt when the Ex domain is bound ([Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}). Ordered density for DNA is not seen at any of the known PIP~2~ binding sites, consistent with observations that PIP~2~ binding sites are not ordered pockets but rather a collection of basic residues that protrude into the solvent ([@bib42]). Notably, phosphoAP2-NECAP binds to the single-stranded DNA construct used in this experiment with an affinity of \~60 nM ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), suggesting that our sample is \>95% bound to DNA at the concentrations used to make cryo-EM grids (3 μM protein, 15 μM DNA). Importantly, only the PIP~2~ binding site on the alpha N-terminus is solvent-exposed in the clamped conformation, so the structural consequences of membrane engagement are fundamentally different in the open (several exposed membrane binding sites) versus the closed (a single membrane binding site) conformations.

After our cryo-EM structure revealed the NECAP~Ex~ binding site, we sought to understand the functional consequences of this interaction. Intriguingly, our genetic screen provided an unexpected insight, as it identified two mutations in the AP2 alpha and beta subunits that escape inactivation by NECAP and are in close proximity to the NECAP~Ex~ binding site ([Figure 2](#fig2){ref-type="fig"}, [Figure 6A](#fig6){ref-type="fig"}). Purified AP2 complexes with these mutations have reduced affinity for NECAP in vitro ([Figure 6B](#fig6){ref-type="fig"}). Additionally, mutation of the most conserved residues of the NECAP~Ex~ domain results in loss of binding to open AP2 ([Figure 6B](#fig6){ref-type="fig"}) ([@bib53]). All three of these mutations recapitulate the NECAP knockout phenotype in our in vivo fitness assay ([Figure 6C](#fig6){ref-type="fig"}), imaging assay ([Figure 6D](#fig6){ref-type="fig"}), and protease sensitivity assay ([Figure 6E](#fig6){ref-type="fig"}). These data support the conclusion that NECAP~Ex~ specifically recognizes membrane-activated AP2.

![The AP2-NECAP~Ex~ interface is required for inactivation.\
(**A**) Residues identified in our genetic screen (see [Figure 2](#fig2){ref-type="fig"}) shown as colored spheres on a ribbon diagram of AP2 with outline of NECAP~Ex~ density (red, low isosurface threshold, see [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). (**B**) Binding curves generated from pulldown depletion assays. Error bars represent mean ± SEM from three technical replicates. Inset: Calculated K~d~ values, variance is SEM. \*p\<0.05, \*\*p\<0.01, relative to control. (**C**) In the absence of NECAP (--), *fcho-1* mutants take about 4 days to proliferate and consume a bacterial food source (fitness defect = 0). Expression of NECAP (+) increases the number of days to about 8 (fitness defect = 1). Data for interface mutants were normalized to this fitness defect; n = 10 biological replicates. (**D**) In *fcho-1; apm-2 (E306K)* mutant worms, NECAP is recruited to the nerve ring. Interface mutants disrupt nerve ring recruitment. Normalized RFP intensities plotted above representative confocal nerve ring images of ten biological replicates. (**C--D**) Error bars indicate mean ± SEM. Significance compared to NECAP (+); Student's t-test performed on raw data (**C**) or normalized data (**D**). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001. (**E**) In vivo protease sensitivity assay to probe AP2 conformation in genetic backgrounds indicated. In the absence of NECAP (--), AP2 is protease sensitive (open). Expression of wild type NECAP (+) results in protease resistant AP2 (closed). All strains lack *fcho-1*. See also [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.](elife-50003-fig6){#fig6}

NECAP clamps AP2 in a closed, inactive conformation {#s2-6}
---------------------------------------------------

Our structural, genetic, and biochemical data suggest a mechanism whereby NECAP clamps AP2 in a closed, inactive conformation via simultaneous engagement of the mu and beta subunits. We tested this hypothesis using our in vitro protease sensitivity assay. We incubated open phosphoAP2 with NECAP and found that including NECAP decreases the protease sensitivity of AP2, consistent with the closed conformation observed in our structure ([Figure 7A](#fig7){ref-type="fig"}, top). Additionally, by comparing various truncations of NECAP we found that both NECAP~PHear~ and NECAP~Ex~ were required for this activity ([Figure 7A](#fig7){ref-type="fig"}). When we measured the protease sensitivity of endogenous AP2 in *C. elegans* expressing NECAP truncations, we saw a similar dependence on NECAP~PHearEx~ for full function ([Figure 7A](#fig7){ref-type="fig"}, bottom). Additionally, we observed that NECAP~PHearEx~ was sufficient to rescue a NECAP deletion in worms using our whole animal fitness assay ([Figure 7B](#fig7){ref-type="fig"}). Taken together, these data show that NECAP~PHearEx~ locks AP2 into an inactivated conformation.

![NECAP clamps AP2 in a closed, inactive conformation.\
(**A**) Analysis of NECAP activity on AP2 protease sensitivity. (Left) Schematic of components. Oligo, 60 nucleotide single-stranded DNA. (Center) Samples analyzed by western blot to quantify cleavage of mu subunit. (Right) Western blots cropped to show uncut mu subunit after either addition of protease (in vitro, top) or protease expression via heat shock promoter (in vivo, bottom). Numbers represent normalized intensity of the uncut mu band, relative to the sample with full length NECAP. (**B**) In the absence of NECAP (--), *fcho-1* mutants take about 4 days to proliferate and consume a bacterial food source (fitness defect = 0). Expression of NECAP (Full length) increases the number of days to about 8 (fitness defect = 1). Data for the truncations were normalized to this fitness defect; n = 10 biological replicates. \*\*\*p\<0.001; ns, not significant; relative to NECAP knockout (-). N = 10 biological replicates. (**C**) Model of AP2 inactivation by NECAP.](elife-50003-fig7){#fig7}

Discussion {#s3}
==========

Our combination of genetic, biochemical, and structural data supports a mechanism by which NECAP inactivates AP2 by initially recognizing open, unphosphorylated complexes and promoting the closed, inactive conformation after phosphorylation ([Figure 7C](#fig7){ref-type="fig"}). Previous work in vertebrate tissue culture suggests that NECAP~Tail~ mediates binding of AP2 through the alpha appendage ([@bib50]). However, NECAP~Tail~ is poorly conserved in *C. elegans* ([Figure 1B](#fig1){ref-type="fig"}) and is dispensable for activity in our assays ([Figure 7A,B](#fig7){ref-type="fig"}) ([@bib6]). This suggests that we have found an additional and perhaps more ancient activity of NECAP, by which the conserved NECAP~PHear~ and NECAP~Ex~ domains cooperate to stabilize the closed conformation of AP2 in a three-step cycle ([Figure 7C](#fig7){ref-type="fig"}). First, AP2 complexes are recruited to the plasma membrane where PIP~2~ and other activators induce the opening and stabilization of the complex ([@bib28]). Next, NECAP~Ex~ recognizes open AP2 complexes and binds to the beta subunit, placing NECAP~PHear~ close to AP2 at a high local concentration. Finally, after AP2 phosphorylation, NECAP~PHear~ engages the mu subunit of AP2 to clamp the complex in a state resistant to activation ([Figure 7](#fig7){ref-type="fig"}). Our data confirm this complex is closed despite the otherwise activating signal of membrane mimetics ([Figure 5B](#fig5){ref-type="fig"}) and is resistant to proteolysis ([Figure 7A](#fig7){ref-type="fig"}). Importantly, this inactivation cycle has a strong dependence on phosphorylation of AP2 ([Figure 3](#fig3){ref-type="fig"}), suggesting that inactivation of AP2 is a tightly regulated mechanism.

In general, data from our vertebrate and *C. elegans* systems are consistent, highlighting the evolutionary conservation of the NECAP-AP2 interaction. However, some of the incongruities in our data show the limitations of translating results between model systems. For example, mutation of R112 in NECAP~Phear~ is less disruptive than mutation of mu T156, despite R112 directly coordinating pT156 in our cryoEM structures ([Figure 2B](#fig2){ref-type="fig"}). It is possible that R112 is not the sole determinant for NECAP binding, and that other residues also aide in coordinating pT156. Indeed, NECAP R89 lies only 5 Å from mu pT156, suggesting that it may also contribute to coordination of the phosphorylation mark. Additionally, we find that the R112 mutation appears less potent in our *C. elegans* assays ([Figure 2D--F](#fig2){ref-type="fig"}) than in pulldowns using vertebrate proteins ([Figure 2C](#fig2){ref-type="fig"}) possibly due to evolutionary variance in how NECAP recognizes the phosphate on AP2. Also, mutations that disrupt NECAP binding to phosphoAP2, such as mu T156A, do not fully abolish recruitment of NECAP to AP2 in our nerve ring assay ([Figure 2E](#fig2){ref-type="fig"}). It is possible that NECAP~Phear~ binding to phosphoAP2 is not a major determinant of NECAP binding in vivo. The residual level of NECAP enrichment could be due to an additional interface between NECAP and AP2, such as NECAP~Ex~ with AP2 beta ([Figure 5](#fig5){ref-type="fig"}) or NECAP~Tail~ with the AP2 alpha ear ([@bib51]).

Indeed, we have proposed an additional interface in our phosphoAP2-NECAP 'clamped' structure obtained in the presence of nucleic acids, in which we observed density contacting AP2 beta ([Figure 5](#fig5){ref-type="fig"}). The resolution of our structure (\~3.5 Å) is not sufficient to unambiguously assign this density to NECAP, but we believe this density is NECAP~Ex~ for several reasons. First, at low isosurface thresholding, the C-terminus of NECAP~PHear~ appears continuous with the new density ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Second, the surface of AP2 beta in contact with this new density is negatively charged and unlikely to bind polyanions such as DNA. Third, an unbiased genetic screen to identify mutations that reduce activity and binding of NECAP in vivo produced two mutations in AP2 that lie beneath this new density ([Figures 2](#fig2){ref-type="fig"} and [6A](#fig6){ref-type="fig"}). However, there still exists the possibility that the density we assign to NECAP~Ex~ actually represents DNA or a portion of NECAP bound to DNA.

If one assumes that our interpretation of the 'clamped' structure is correct, then most of our model ([Figure 7](#fig7){ref-type="fig"}) is directly supported by cryo-EM structures. An exception is the depiction of NECAP~Ex~ interacting with an open, unphosphorylated AP2 complex. We have not resolved a structure for this complex, and instead propose its existence based on biochemical and in vivo data. AP2 complexes that have been incubated with polyanion membrane mimetics adopt an open conformation according to protease sensitivity and cryo-EM ([Figure 4](#fig4){ref-type="fig"}). We observe that NECAP~Ex~ binds these complexes in the absence of phosphorylation ([Figure 5A](#fig5){ref-type="fig"}). We propose that this AP2-NECAP~Ex~ complex occurs early in the AP2 cycle for two main reasons. First, the active state of AP2 appears to induce phosphorylation in vivo, suggesting that AP2 opens on the membrane prior to phosphorylation ([@bib27]). Thus, NECAP~Ex~ can engage open AP2 complexes before phosphorylation and subsequent NECAP~PHear~ binding. Second, NECAP is observed early at sites of endocytosis ([@bib58]) and can be incorporated into the coat, apparently without inhibiting pit assembly ([@bib56]). A priming interaction of NECAP~Ex~ with activated AP2 is consistent with these observations; initially, NECAP is not competent to inactivate AP2, but is poised to do so later in the cycle, after phosphorylation ([Figure 7C](#fig7){ref-type="fig"}).

While we have uncovered new molecular details of how an endocytic regulator can inactivate the AP2 complex, how this process is controlled both spatially and temporally remains an open question. One possibility is that NECAP action is dictated by the timing of AP2 kinase recruitment or activation ([@bib13]; [@bib29]) and that AP2 complexes become inactivated by NECAP immediately upon phosphorylation. Another possibility is that NECAP cannot inactivate stabilized AP2 complexes, but only complexes that are not yet fully initiated, thereby serving as a quality control mechanism ([@bib2]; [@bib11]; [@bib16]; [@bib47]). However, NECAP is reported at endocytic structures ([@bib56]) coincident with the arrival of clathrin ([@bib58]), suggesting that NECAP may act later in the endocytic cycle, after AP2 activation. More speculatively, it is possible that clathrin adaptor inactivation may be involved in vesicle uncoating, as closed AP2 complexes cannot interact with cargo ([@bib12]; [@bib30]; [@bib33]) and a clathrin-binding motif on the beta hinge is occluded in this conformation ([@bib34]). The results of this study do not distinguish whether NECAP acts early in endocytosis to promote productive pit formation by limiting aberrant events, or late in the endocytic cycle to uncoat AP2 and allow the complex to initiate new pits. Regardless of when NECAP acts, AP2 must release NECAP and be dephosphorylated to regenerate the steady-state cytosolic pool. It remains to be determined whether NECAP~PHear~ must disengage prior to dephosphorylation, or whether a phosphatase plays a role in NECAP removal from closed complexes.

During review of this manuscript, another study involving AP2, NECAP, and the role of phosphorylation was published ([@bib64]). This study reports a solution structure of NECAP~PHear~ bound to a fragment of the phosphorylated mu linker (AA 149--163) that agrees with our cryo-EM structures. Their data supports the notion that phosphorylation is a key determinant in the timing and action of NECAP in the AP2 regulatory cycle, a finding generally consistent with this study. However, Wrobel et al. propose an activating role for AP2 phosphorylation and NECAP, which directly counters our model for NECAP action.

It is also not clear whether NECAP has functions apart from regulation of AP2. For example, the phosphorylated threonine of the AP2 mu subunit is conserved on the mu subunit of AP1 ([@bib21]; [@bib24]; [@bib48]) and NECAP has been proposed to both interact with and control AP1 ([@bib9]; [@bib51]). This suggests a broader role for NECAP and regulated adaptor inactivation at other membrane compartments.

Materials and methods {#s4}
=====================

*C. elegans* strains, recombinant proteins, DNA plasmids (including cloning strategies), sequences of synthesized gene fragments (IDT gBlocks), and sequences of DNA oligos are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}: Key Resources Table.

Model system {#s4-1}
------------

*C. elegans* were maintained at room temperature (22--25°C) using standard procedures ([@bib7]) on nematode growth medium (NGM) plates seeded with *E. coli* strain OP50.

Fitness assay {#s4-2}
-------------

Fitness (starvation) assays were performed as previously described ([@bib27]). Briefly, three young adult *C. elegans* hermaphrodites were placed on NGM plates with bacterial food source. The number of days for the population of worms to expand and consume the food was recorded.

Transgenic strains {#s4-3}
------------------

Generation of transgenic strains by CRISPR was performed as previously described ([@bib6]) using ribonucleoprotein complexes ([@bib43]). Injection mixes contained 19 μM recombinant Cas9 nuclease (purified in-house), 30 μM crispr RNA (crRNA) for desired edit (IDT), 35 μM trans-activating crRNA (trRNA, IDT), 6 μM crRNA targeting the *dpy-10* locus (IDT), and 2.5 μM *dpy-10 (rol)* single stranded oligo repair template (IDT). For small missense mutations, 10 μM single-stranded oligonucleotide (oligo) DNA repair template (IDT) was included. For large insertions, such as fluorophores, repair templates (PCR products with 35 base pair homology arms flanking the Cas9 cleavage site) were included at a final concentration of 1 μM. Gonad arms of young adult hermaphrodite *C. elegans* were injected and *rol* F1 offspring of the injected worms were transferred to a fresh plate, allowed to lay eggs, and genotyped for the desired edit. Non-*rol* F2 offspring were similarly screened to isolate worms with homozygous edits. GUN89 was generated using mos1-mediated single copy insertion as previously described ([@bib6]; [@bib20]) by injecting targeting vector pEP57 into *C. elegans* strain EG6703.

Mutagenesis screen {#s4-4}
------------------

*C. elegans* strains GUN61 or GUN88 (*fcho-1* mutants expressing *RFP:NECAP*) were mutagenized in 0.5 mM N-nitroso-N-ethylurea (ENU, Sigma Aldrich N3385) for 4 hr at 22°C. After washing with M9 buffer, animals were distributed onto growth plates (10 cm NGM plates seeded with concentrated bacterial OP50 culture). Once the worm population had expanded and consumed the food source, ∼2 × 2 cm pieces of each plate were transferred to a fresh growth plate. This process was repeated 4--6 times to select for genotypes with greater fitness, which were then visually screened to eliminate NECAP knockouts (RFP negative) and open AP2 mutations (nerve-ring-enriched RFP). Genomic regions corresponding to AP2 subunits and NECAP were amplified by PCR and sequenced in candidate interface mutants. To confirm that the mutations we identified were responsible for the observed phenotypes, we generated them de novo using CRISPR.

Recombinant protein purification {#s4-5}
--------------------------------

### AP2 complex purification {#s4-5-1}

AP2 cores were purified as described previously ([@bib27]) with some modifications. Plasmids encoding wild type or mutant AP2 cores were expressed in *E. coli* (BL21 DE3, NEB). To generate phosphorylated AP2 cores, a plasmid encoding the kinase domain of AAK1 was included. *E. coli* cultures (500--6000 mL) expressing the AP2 cores were lysed by sonication in 50 mM Tris pH 8.0, 1000 mM NaCl, 10% glycerol, 10 mM MgCl~2~, 1 mM CaCl~2~, 150 ng/μL lysozyme (Sigma), 24 ng/μL DNAse (grade II from bovine pancreas, Roche), 1 mM Phenylmethylsulfonyl fluoride (PMSF), and one cOmplete EDTA-free Protease Inhibitor Cocktail tablet (Roche). Clarified lysate was passed over a column packed with GST resin to bind AP2. Column was washed with 50 mM Tris pH 8.0, 1000 mM NaCl, 10% glycerol, and 1 mM DTT until optical density at 280 nm (OD280) of the flow-through was below 0.05 arbitrary units (AU). Column was then washed in TBS-DTT (20 mM Tris pH 7.6, 150 mM sodium chloride, and 1 mM DTT) prior to elution. Complexes were eluted using glutathione elution buffer (50 mM Tris, 150 mM sodium chloride, 10 mM reduced glutathione, 1 mM DTT, final pH 9.0) or treated with GST-HRV protease (purified in-house) to release AP2 from the GST affinity tag. Eluted complexes were buffer-exchanged with TBS-DTT and concentrated by centrifugal filtration to 1--5 μM before snap-freezing in liquid nitrogen for long-term storage.

### Hexahistidine-tagged (6xHis) protein Purification {#s4-5-2}

Hexahistidine-tagged proteins were purified as described previously ([@bib6]; [@bib27]) with some modifications. *E. coli (*BL21 DE3, NEB; 500 mL culture) expressing hexahistidine-tagged proteins were lysed by sonication in 50 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, 10 mM MgCl~2~, 1 mM CaCl~2~, 150 ng/μL lysozyme (Sigma), 24 ng/μL DNAse (grade II from bovine pancreas, Roche), 1 mM PMSF, and one cOmplete EDTA-free Protease Inhibitor Cocktail tablet (Roche). Clarified lysate was passed over a column packed with TALON resin (Clontech) to bind the hexahistidine-tagged protein. The column was first washed with 50 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, and 5 mM BME until the OD280 of the flow-through was below 0.05 AU. Column was then washed with TBS-BME (20 mM Tris pH 7.6, 150 mM sodium chloride, and 5 mM BME), and the bound protein was eluted using TBS-BME supplemented with 150 mM imidazole. Proteins were buffer exchanged with TBS-DTT and concentrated to 100 μM by centrifugal filtration before snap-freezing in liquid nitrogen for long-term storage.

### phosphoAP2-NECAP purification {#s4-5-3}

E.*E. coli* (BL21 DE3, NEB; 500--6000 mL culture) expressing phosphoAP2 core (pGH504/pGH419/pEP82) or phosphoAP2 (mu E302K) core (pGH504/pGB106/pEP82) were prepared as in *AP2 complex purification* above, until after the wash steps. Before elution, 10 mg purified mouse NECAP2:6xHis (pGH503) was flowed over the resin in a total volume of 25 mL TBS-DTT. Column was washed in 50 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, 5 mM BME. The complex was released from the GST affinity tag by incubation with GST-HRV protease (purified in-house). The phosphoAP2-NECAP complex was further purified using a column packed with TALON resin to remove AP2 that was not bound to 6xHis-tagged NECAP. Column was washed with 50 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, 5 mM BME. The complex was eluted using 50 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, and 5 mM BME supplemented with 150 mM imidazole. The sample was concentrated to OD280 of \~4 AU and further purified using gel filtration (Superdex 200 Increase 10/300 GL column, General Electric). The sample was buffer exchanged with 20 mM HEPES pH 8.0, 150 mM KCl, 1 mM DTT during gel filtration. The final complex was concentrated to \>10 μM before snap-freezing in liquid nitrogen for long-term storage.

In vitro pulldowns {#s4-6}
------------------

Pulldown assays were performed essentially as described ([@bib27]) except the protease cleavage step was 3--6 hr. For the pulldown assay, 80 pmol of purified HaloTag:NECAP bait or HaloTag control, 40 pmol of recombinant AP2 prey, and 10 μL of Magne HaloTag Bead slurry (20%, Promega) were mixed in TBS-DTT (1 mL total volume for each pulldown) and nutated overnight at 4°C. For pulldowns with 'open AP2', 100 μg heparin was also included. After incubation, the beads were washed with TBS-DTT and bound proteins were cleaved from the HaloTag by incubation with TEV protease (purified in-house, 3--6 hr at 22°C). Eluted proteins were visualized by coomassie-stained sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Images in manuscript are cropped to show the largest AP2 band for each prey (alpha:GST, or alpha and beta).

Pulldown depletion assay {#s4-7}
------------------------

To determine the K~d~ of NECAP for open AP2, we measured how much AP2 was precipitated by various concentrations of immobilized NECAP. Open AP2 (50 nM AP2 mu E302K with 10 ng/μL heparin) was incubated with HaloTag:NECAP2:6xHis (30--3000 nM) and TALON hexahistidine affinity resin (20 μL) in TBS-T (20 mM Tris pH 7.6, 150 mM NaCl with 0.1% Tween-20, final reaction volume 100 μL). Samples were agitated at 1500 rpm for one hour at 22°C. The resin was allowed to settle and 45 μL of the supernatant was analyzed by coomassie-stained SDS-PAGE.

In vitro protease assay {#s4-8}
-----------------------

This assay was used to measure the conformation of AP2 complexes in vitro. A thrombin protease site (DNA sequence 5'-ctggtgccgcgcggcagc-3') was inserted into the mu subunit after residue S236. This protease site becomes exposed when AP2 adopts the open conformation. To perform the assay, 20 pmol of purified AP2, 3.3 μg of activators (oligo DNA, plasmid DNA, RNA, or heparin), and 50 pmol of HaloTag:NECAP or 50 pmol of HaloTag control were mixed in 30 μL TBS-DTT. Thrombin protease (Sigma T7009, 3 μL) was then added (see amounts and timings below). Reactions were incubated at 22^o^ C for 10 min (0.25 U thrombin, [Figure 4B](#fig4){ref-type="fig"}) or 30 min (0.5 U thrombin, all others) and terminated by addition of 11 μL 4X bolt LDS Sample Buffer (ThermoFisher) and incubation at 95^o^ C for 5 min. Cleavage of the mu subunit was analyzed by coomassie-stained SDS-PAGE ([Figure 4B](#fig4){ref-type="fig"}) or by western blot for the phosphorylated mu subunit ([Figure 7A](#fig7){ref-type="fig"}, top). The primary antibody was rabbit anti-AP2M1 phospho T156 (1:1000, Abcam 109397), and the secondary antibody was goat anti-rabbit Alexa Fluor 647 (1:2000, Life Technologies, A21244).

In vivo protease assay {#s4-9}
----------------------

In vivo TEV assays were performed as previously described ([@bib6]). *C. elegans* strains used in this assay express heat-shock inducible TEV protease and an AP2 mu transgene containing a TEV protease site that is exposed specifically when AP2 is in an open conformation. The strains also express an RFP:NECAP transgene or RFP alone. 100 L4 stage *C. elegans* hermaphrodites were picked from a growth plate either before or 6 hr after a 1 hr heat shock (34°C). Worms were placed in 1 mL of 20 mM Tris pH 7.6, 150 mM NaCl (TBS) with 0.001% Triton X-100. Animals were pelleted at 1000 g and washed once with TBS containing 0.001% Triton X-100. Samples were pelleted again and the supernatant removed, leaving behind 45 μL total volume. 15 μL 4x bolt LDS Sample Buffer supplemented with fresh dithiothreitol (DTT) was added, and sample was snap frozen in liquid nitrogen. Samples were then lysed in a cup horn sonicator (Branson Ultrasonics Corporation, Danbury, CT; 1 s pulses at 90--95% amplitude for 2--3 min) followed by heating to 70 °C for 10 min. Samples were re-sonicated following the 70 °C denaturation step if any exhibited excessive viscosity. The entire sample was separated by SDS-PAGE and western blot analysis was performed to detect the 3xFLAG-tagged mu subunit. The primary antibody was mouse anti-flag (1:1000, Sigma-Aldrich F3165), and the secondary antibody was goat anti-mouse IRDye 800CW (1:20000, LI-COR, 925--32210).

In vivo imaging assay {#s4-10}
---------------------

Nerve ring imaging was performed as previously described ([@bib6]) with modifications to data quantification. Live worms were immobilized on slides and imaged on a Zeiss LSM 880 confocal microscope with a 40x water immersion objective. Fluorophores were excited with 488 nm (GFP) and 561 nm (RFP) lasers. Strains for each experiment were imaged in one session with the same laser settings. For each worm, a single confocal slice through the approximate sagittal section of the nerve ring was analyzed in Fiji. The GFP-AP2 signal corresponding to the nerve ring was used to define a region of interest (ROI) for quantification of 'nerve ring RFP'. A second ROI in the anterior of the worm that was outside the nerve ring and pharynx was used for normalization.

Cryo-EM structure determination {#s4-11}
-------------------------------

The following conditions were used for all cryo-EM samples. Grids were prepared by glow discharging UltraAuFoil R 1.2/1.3 300 mesh gold grids (Quantifoil GmbH) for 30 s at 20 mAmp. Grids were used within 10 min of charging. 4 μL of sample was applied to grids and plunge frozen in liquid ethane using a Vitrobot Mark IV robot (Thermo Fisher) set to 100% humidity, 4 °C, blot force 20, and blot time 4 s. Samples were imaged using a Talos Arctica TEM (Thermo Fisher) operating at 200 keV in nano probe mode and equipped with a K2 Summit Direct Electron Detector (Thermo Fisher). Parallel illumination of the microscope was performed according to [@bib26]. Images were collected at 36,000x, yielding a final pixel size of 1.16 Å for counting mode and 0.58 Å for super resolution mode. Dose fractionated movies were collected at a defocus range of −0.6 µm and −2.5 µm and an exposure rate of \~6 e-/pixel/s with 200 ms frames and a total exposure of \~50 e-/Å^2^. New camera gain references were collected before each dataset and the hardware dark reference was updated daily. The microscope was operated using the Leginon software suite ([@bib57]) and data were processed on the fly using the Appion software suite ([@bib36]), including motion correction and gain correction using MotionCor2 ([@bib65]), CTF estimation using CTFFIND4 ([@bib54]), and particle picking using DogPicker.py ([@bib61]). Particles were extracted from dose-weighted, aligned micrographs and analyzed using cryoSPARC ([@bib46]) and Relion-3 ([@bib40]). Unless otherwise noted, resolution values are according to the 0.143 gold standard Fourier shell correlation (GSFSC) method ([@bib55]).

### phosphoAP2-NECAP cryo-EM structure determination {#s4-11-1}

The phosphorylated AP2 core was purified in complex with full-length mouse NECAP2 using recombinant expression in *E. coli* and used to make cryo-EM grids (see *phosphoAP2-NECAP purification*, above). The final protein buffer was 20 mM HEPES-KCl, pH 8.0, 150 mM KCl, 1 mM DTT. We noticed that particles had a different orientation in the ice based on protein concentration and/or the presence of a detergent, n-Octyl-β-D-Glucopyranoside (β-OG) ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). To increase the angular distribution of the particles in the final dataset, three datasets (5 µM protein, 1 µM protein, and 5 µM protein + 0.05% w/v β-OG) were collected using the same exposure rate, total exposure, frame rate, and magnification, then merged and processed as a single dataset. A total of 1092 movies were collected and 944 remained after removing micrographs with crystalline ice or CTF fits worse than 3.5 Å as judged by the 0.5 criterion in Appion. 890,658 particles were extracted, subjected to multiple rounds of 2D classification and re-extraction in Relion-3, yielding a dataset of 490,560 'clean' particles. These particles were used to generate an *ab initio* 3D model in cryoSPARC, which was used as a search model for 3D classification and 3D auto-refinement in Relion-3. After masking and postprocessing, this yielded a 3.7 Å resolution map. After local CTF refinement and beam-tilt estimation in Relion-3, the resolution improved to 2.9 Å resolution. While the AP2 core was well resolved, the density for NECAP was lower resolution (\~4.5 Å local resolution), preventing us from building an accurate model. Signal subtraction ([@bib5]) and 3D classification without alignment were used to find a sub-population that refined to 3.2 Å resolution, but with significantly improved density for NECAP. Local resolution estimation was performed using Relion-3, showing a range from 3.1 to 4.2 Å resolution, with the bulk of the model below 3.5 Å. This final map was used for model building, see *Model building and validation*, below.

### phosphoAP2-NECAP (mu E302K) + DNA cryo-EM structure determination {#s4-11-2}

The phosphorylated AP2 core containing a hyper-active mu E302K mutation was purified in complex with full-length mouse NECAP2 using recombinant expression in *E. coli* (see *phosphoAP2-NECAP purification* above). The final protein buffer was 20 mM HEPES-KCl, pH 8.0, 150 mM KCl, 1 mM DTT, 0.05% w/v β-OG. phosphoAP2-NECAP (mu E302K) at 3 µM concentration was mixed with 15 μM of a 60 bp single-stranded DNA oligo (oEP971) and used to make cryo-EM grids. A total of 1497 movies were collected and 1126 remained after removing micrographs with crystalline ice or CTF fits worse than 3.5 Å. 717,231 particles were extracted, subjected to multiple rounds of 2D classification and re-extraction in Relion-3, yielding a dataset of 388,962 'clean' particles. These particles were used to generate an *ab initio* 3D model in cryoSPARC. 324,922 particles were found to go into high-resolution classes using heterogeneous refinement, and a final refinement was performed using the non-uniform refinement protocol in cryoSPARC v2, yielding a final resolution of 3.5 Å. Map sharpening and local resolution estimation was performed using cryoSPARC v2.

### Model building and validation {#s4-11-3}

For each AP2-NECAP complex, the same general process was followed. The crystal structure of the AP2 complex in the closed conformation (PDB 2VGL) ([@bib12]) and the solution structure of mouse NECAP1 (PDB 1TQZ) ([@bib52]) were docked into the cryo-EM map using Chimera ([@bib45]). First, NECAP was manually rebuilt in Coot to match the cryo-EM density. A round of real space refinement was performed in Phenix using phenix.real_space_refine ([@bib1]). Regions of AP2 absent from the PDB 2VGL model were manually built in Coot ([@bib17]), including a region of the mu subunit containing phosphorylated T156 (AA154-158). The NECAP model was then improved using RosettaCM and Rosetta *FastRelax* integrated into a cloud-based cryo-EM pipeline ([@bib10]; [@bib62]; [@bib63]). At this point, a full phosphoAP2-NECAP model was generated and used as a starting model to generate \~1000 models using RosettaCM. The model with the lowest energy score was then used to generate 100 models in Rosetta *FastRelax*. The lowest energy model from this analysis was further refined using phenix.real_space_refine. For the 'unclamped' phosphoAP2-NECAP model, the following side chains were truncated to the Cβ atom (alpha residue 11; beta residue 5; mu residue 253, 261, 379, 380; NECAP residues 62, 102). For the 'clamped' phosphoAP2-NECAP model, the following side chains were truncated to the Cβ atom (alpha residue 11, 123, 217, 341, 381; beta residue 5, 26, 27, 232; mu residue 21, 26, 261, 281, 379, 380; NECAP residues 94, 101, 102, 137). Additionally, a short poly-alanine peptide was modeled into the NECAP~Ex~ density and included during model refinement for the 'clamped' structure.

### 2d and 3d classification of 'open' vs 'closed' AP2 complexes {#s4-11-4}

AP2 and AP2 (mu E302K) were purified using recombinant expression in *E. coli* (see *AP2 complex purification* above). Cryo-EM grids were prepared with 3 μM protein with or without a 5x molar excess of a 60 bp single-stranded DNA oligo (oEP971, same as that used in protease assay). Gel shift assays showed that phosphoAP2 (mu E302K)-NECAP has a Kd of \~60 nM for the DNA oligo used for cryo-EM (=[Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"} ). Assuming a single binding site, AP2 is expected to be \>98% bound at the concentrations used for our cryo-EM analysis. Four datasets in total were collected: AP2, AP2 + DNA, AP2 (mu E302K), AP2 (mu E302K) + DNA. Particles were extracted and analyzed in Relion-3. For each sample, we first performed several rounds of 2D classification, yielding about \~50% of particles that entered classes with well-resolved secondary structure. After this initial cleaning step, each particle set was randomly split into 10 subsets and subjected to 2D and 3D classification. For 2D classification, subsets were divided into 40 classes. For 3D classification, the initial model was filtered to 30 Å and six classes were used (T = 4, K = 6). Quantification of particles in the 'open' vs. 'closed' conformation is described in the following section.

Quantification and statistical analysis {#s4-12}
---------------------------------------

### Fitness assays {#s4-12-1}

Measurements of number of days to starve were taken from 10 biological replicates for each strain. Significance was calculated using an unpaired, two tailed T-test with Prism GraphPad software. Data was normalized relative to NECAP (-) and NECAP (+) strains for visualization only.

### Pulldown depletion assays {#s4-12-2}

Three technical replicates were performed for each sample. Alpha:GST band intensity was quantified (AP2^MEASURED^) and these values were plotted against NECAP concentrations on a logarithmic scale. A sigmoidal (4PL) fit was applied to the data using GraphPad Prism 7.04. The asymptote representing the maximum AP2 that would remain in solution at zero NECAP concentration was calculated (AP2^MAX^). The 'fraction AP2 bound' in each sample was then calculated using the formula (1 -- \[AP2^MEASURED^/AP2^MAX^\]). These normalized values were then plotted against NECAP concentrations on a logarithmic scale and an EC50 (K~d~) was calculated from a sigmoidal (4PL) fit of the data using GraphPad Prism 7.04. Note that for [Figure 6B](#fig6){ref-type="fig"}, 'fraction AP2 bound' was plotted against the concentration of NECAP on a linear scale.

### In vivo imaging assays {#s4-12-3}

Strains for each experiment were imaged in one session with the same laser settings. For each worm, a single confocal slice through the approximate sagittal section of the nerve ring was analyzed in Fiji. The GFP-AP2 signal corresponding to the nerve ring was used to define a region of interest (ROI) for quantification of 'nerve ring RFP'. A second ROI in the anterior of the worm that was outside the nerve ring and pharynx was used for normalization. 'Nerve ring RFP' was quantified as the average fluorescent intensity in the nerve ring ROI divided by the average fluorescent intensity in the ROI for normalization. Images were analyzed for ten biological replicates, and significance was calculated using an unpaired, two tailed T-test with Prism GraphPad software.

### 2d and 3d classification of 'open' versus 'closed' AP2 complexes {#s4-12-4}

Four datasets in total were collected: AP2, AP2 + DNA, AP2 (mu E302K), AP2 (mu E302K) + DNA, as described in the previous section. After identifying particles from each dataset that fit into well-defined 2D classes, each particle set was randomly split into 10 subsets (technical replicates) and 2D and 3D classified in Relion-3. For each random subset subjected to 2D classification, classes were divided into 'open' or 'closed' conformations based on projection matching with the 'open' (PDB 2XA7) ([@bib30]) and 'closed' (PDB 2VGL) ([@bib12]) crystal structures. Projection matching was performed in SPIDER ([@bib19]) with in-house scripts. For 3D classification, classes were determined to be 'open' or 'closed' based on visual inspection and docking of crystal structures using UCSF Chimera. The ten measurements of 'open' vs. 'closed' were used to calculate a standard error of the mean (SEM).

Data and code availability {#s4-13}
--------------------------

The density maps generated during this study are available at the Electron Microscopy Data Bank (EMD-20215, unclamped and EMD-20220, clamped); the atomic structures generated during this study are available at the Protein Data Bank (PDB 6OWO, unclamped and 6OXL, clamped).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A structural mechanism for phosphorylation-dependent inactivation of the AP2 complex\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Suzanne Pfeffer as the Senior and Reviewing Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As summarized by reviewer 1, This submission is a logical and illuminating extension of work from the Hollopeter lab. Using combined structural, biochemical and worm-based approaches, an appealing model for AP2 mu2 adaptin phosphorylation and NECAP binding in returning AP-2 to the closed conformation is proposed. The work documents five substantial advances:

1\) Cryo-EM structures of recombinant phosphorylated AP2 core bound to NECAP2 as well as to the non-phosphorylated open form of AP2.

2\) The formulation and use of various polymeric negatively charged membrane mimetics to dissect NECAP-AP2 interactions.

3\) The identification that the middle \"Ex\" region of NECAP recognizes the membrane bound open AP2 core without a requirement for phosphorylation.

4\) A bivalency model for AP2 closure based upon the data collected.

5\) The description that the NECAP clamped AP2 structure functionally deactivates all but the α adaptin PIP2 binding sites.

Overall, the reviewers would be in favor of presentation of the story in *eLife* if you are able to address the concerns of reviewer \#2. After carefully evaluating your data he wrote, \"I think the authors did an excellent job interpreting their density, but their maps are not so easy to interpret. The challenge in assigning the phospho-Thr156 position, in particular, arises because there is a big gap in the EM map that breaks the connectivity. The authors modeled up to Ser140 for AP-2 mu, but then the density washes out completely, and the authors couldn\'t resume modeling until \~Gln154. This assignment looks like a good guess because there are three \"landmark\" residues further down the chain that fit the density well for a \~3A map: Trp161, Arg162, and Try168. In summary, because their map is discontinuous, it is hard to be confident in the register of their atomic model. Nevertheless, their model is parsimonious and a very good guess, based on the fit-to-density and spacing between Trp161, Arg162 and Tyr168. My recommendation is that they tackle this issue head-on and use clearer figures to illustrate how the landmark residues support their decision to resume modeling the chain at Gln154.

My other comments may be harder to address. Given the uncertainty around the modeling of Thr156, their combination of protease accessibility, worm fitness, localization microscopy, and genetic suppressors, altogether, leaves some room for doubt. Finally, the use of 2D cryoEM class averages to support their claim of an induced open state does not convince me. If they have an open state in solution due to interactions with polyanions, they should be able to resolve it in 3D, not just in 2D.\"

We would welcome a revised manuscript that addresses these issues and/or clarifies the conclusions so that there is no confusion for readers. We hope you will find these comments constructive, and I include the details to help guide your revision process.

*Reviewer \#1:*

This submission is a logical and illuminating extension of work from the Hollopeter lab. Using combined structural, biochemical and worm-based approaches, an appealing model for AP2 mu2 adaptin phosphorylation and NECAP binding in returning AP-2 to the closed conformation is proposed. The quality of the data is high. The work is nicely presented and documents of five substantial advances:

1\) Cryo-EM structures of recombinant phosphorylated AP2 core bound to NECAP2 as well as to the non-phosphorylated open form of AP2.

2\) The formulation and use of various polymeric negatively charged membrane mimetics to dissect NECAP-AP2 interactions.

3\) The identification that the middle \"Ex\" region of NECAP recognizes the membrane bound open AP2 core without a requirement for phosphorylation.

4\) A bivalency model for AP2 closure based upon the data collected.

5\) The description that the NECAP clamped AP2 structure functionally deactivates all but the α adaptin PIP2 binding sites.

Together, this provides important and novel structural insight into the conformational changes needed for AP2 function.

Because of the rather limited Discussion section, my concerns are more at the level of interpretation and explanation than with the primary data itself. In the Introduction, the authors indicate AP2 inactivation may also regulate abortive events, but do not clearly explain this at the end in light of the structural findings. They do not seriously consider why NECAP is recruited to CCPs quite early, as seen in time-resolved live cell imaging and clearly a steady-state component of bulk CCPs; they vacillate between this being possibly related to abortive disassembly or perhaps indicative of a role later in CME. They do not discuss how multiple site bound NECAP detaches from the locked state to allow dephosphorylation, which must explain the bulk cytosolic population of AP-2 that is closed but dephosphorylated. In other words, they do not explore why NECAP is not bound stoichiometrically to the cytosolic pool of closed AP2.

As far as I can follow, the authors used mouse NECAP2 for their studies. However, there is published data that show NECAP2 is unnecessary for CME, that NECAP1 and -2 have functionally diverged (cannot rescue knockdown of the other paralog), and that NECAP2 instead regulates AP1 during endosomal recycling. Better justification/rationalization of the choice of NECAP2 is required.

There are now three reports of inherited NECAP1 mutations associated with human neurological disease, and also a reported disease-associated NECAP1 mutation in dogs. How these mutations are related to the structural functional findings in this works should be addressed for the general reader.

Reviewer \#2:

Partlow et al. report cryoEM structures of the phosphorylated AP-2 complex bound to its regulator, NECAP. AP-2 is thought to cycle between a \"closed\", inhibited conformation in the cytosol and an \"open\", membrane-bound state during endocytosis. AP-2 is phosphorylated, but whether phosphorylation promotes AP-2 opening and endocytosis-or AP-2 closing to inhibit endocytosis-remains controversial. A subset of these authors proposed previously that NECAP, a negative regulator of endocytosis, binds to phosphorylated and open-conformation AP-2-and this hypothesis motivated their current cryoEM structural study of NECAP-bound and phosphorylated AP-2. Combined with an impressive set of genetic observations and biochemical binding experiments, this study could clarify NECAP\'s role in regulating endocytosis through regulatory phosphorylation. However, in its current form the manuscript is confusing and makes what seem like unwarranted leaps in interpretation.

1\) At this average resolution, and from the figures presented, I am not yet confident in the model building for AP-2 mu, especially Thr156-Phospho. Would the authors be willing to provide the experimental maps and models for direct inspection? Do the cryoEM maps allow for unambiguous assignment of the amino acid register for AP2 mu subunit residues 154-158? Are the two phospho maps, phosphoAP2-NECAP-DNA \'clamped\' versus phosphoAP2-NECAP closed consistent in this region, and do independent modeling efforts cross-validate?

2\) Related to point 1, there seem to be mismatches between the structure-based mutagenesis (where R112 plays a major role in coordinating the phosphate), the genetic assays, and the protease sensitivity assay. Specifically, R112 (R109 in worms) was not found as a genetic hit, while A32 (A29 in worms), which is rather far away and not obviously involved in Thr156-phospho binding, was found genetically along with S87 (S84 in worms). S87N and R112E phenocopy in the mouse-based protein pulldown experiment, moreover, but in worms scored for fitness S84N does NOT phenocopy R109E. In the worm nerve ring localization experiment, NECAP R109E and S84N DO phenocopy. Finally, in the protease sensitivity assay, R109E does NOT phenocopy S84N or AP-2 mu T160A. Together with my uncertainty about the register for the structural model, it is unclear to me how to synthesize these observations into an internally consistent model.

3\) The use of polyanion membrane mimetics to stabilize conformationally \"open\" AP-2 lead to further confusion. Specifically, the authors argue that their protease sensitivity assay and 2D class averages reveal how polyanions promote the formation of an open AP-2 complex (although we never see this open state in 3D). They propose that NECAP binds this open state, selectively, in the presence of anions like heparin. Their 3D cryoEM of supposedly activated AP-2 bound to ssDNA and NECAP, however, is of a closed conformation AP-2 that the authors refer to as \"post-open.\" This seems like an unwarranted leap since the structure of the closed-state AP-2 that resolves the NECAPPHEAR domain looks very similar to the structure of the closed-state AP-2 with both NECAPPHEAR and NECAPExTail resolved. Rather, it seems NECAP binds and stabilizes the AP-2 closed state with or without polyanions, and it\'s hard to know why new, hard-to-interpret cryoEM density resolves in the ssDNA-incubated state. Overall, I am not yet convinced that NECAP binds \"open\" AP-2 and do not see how the structures reveal NECAPExTail \"specificity for open complexes\". The cartoon model in Figure 7C illustrates presumed states that are not based on these NECAP-bound structures: the ExTail domain binding to an \"open\" but not phosphorylated AP-2, and both the PHEAR and ExTail domains bound to an \"open\" and membrane-associated AP-2.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A structural mechanism for phosphorylation-dependent inactivation of the AP2 complex\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Suzanne Pfeffer as the Senior and Reviewing Editor, and one reviewer.

The reviewer was convinced by your response to the initial round of comments. He had a few remaining issues however, and we agreed that if you address these directly in a revised discussion (as possible limitations, whether you think they are likely or not), we would be happy to present your story as an *eLife* Research Advance.

The reviewer wrote, \"I am convinced that the structural models that include phospho-Thr156 are sound and that the structure of NECAP bound to this moiety is an important advance.

The rest of my comments are, admittedly, nit-picking. I raise them for discussion, not to stand in the way of publishing an interesting study. First, I remain concerned that the functional tests of the structural model were somewhat inconsistent, as I noted previously. Yes, the assays are very different and have different sensitivities and dynamic ranges. But it is still puzzling that the R109E mutant looks more-or-less indistinguishable from WT in the rescue experiments of Figure 3E-F, while mutating Thr156 (160 in the worm) is a clear loss-of-function in 3F, but not in 3E.\" Please discuss.

\"...Also, I remain concerned about the experiments that rely on anionic polymers to mimic PIP2-containing membranes. The authors may be right, DNA and heparin may be transiently inducing structural changes that are akin to membrane-induced opening, but does it follow from this premise that inositol hexakisphosphate should block the effect of these mimetics on AP2? If heparin, RNA and DNA work, why doesn\'t IP6 also work to open the complex? Because purifying AP2 required high ionic strength solutions (500mM to 1M), but the binding studies done with heparin were done at 150mM NaCl, perhaps non-specific electrostatic \"stickiness\" may be confounding? A less interesting interpretation of the \"post-open\" clamped structure is that the new density is non-specifically bound DNA or some combination of a portion of the Ex domain and DNA.\" Please discuss.

Finally, please include the Molprobity and Clashscore percentiles as well as the absolute scores, as requested previously.

10.7554/eLife.50003.032

Author response

> Overall, the reviewers would be in favor of presentation of the story in eLife if you are able to address the concerns of reviewer \#2. After carefully evaluating your data he wrote, \"I think the authors did an excellent job interpreting their density, but their maps are not so easy to interpret. The challenge in assigning the phospho-Thr156 position, in particular, arises because there is a big gap in the EM map that breaks the connectivity. The authors modeled up to Ser140 for AP-2 mu, but then the density washes out completely, and the authors couldn\'t resume modeling until \~Gln154. This assignment looks like a good guess because there are three \"landmark\" residues further down the chain that fit the density well for a \~3A map: Trp161, Arg162, and Try168. In summary, because their map is discontinuous, it is hard to be confident in the register of their atomic model. Nevertheless, their model is parsimonious and a very good guess, based on the fit-to-density and spacing between Trp161, Arg162 and Tyr168. My recommendation is that they tackle this issue head-on and use clearer figures to illustrate how the landmark residues support their decision to resume modeling the chain at Gln154.

We agree with the reviewer that building the AP2-NECAP interface, and in particular the mu pT156 residue, is vital to our understanding of NECAP function. We acknowledge that how we defined the register of the linker region should be clarified. As suggested by the reviewers, we have added an additional supplementary figure (Figure 1---figure supplement 3) that specifically highlights how we built the mu linker. This shows the docking of the AP2 crystal structure and the 5 residues we built into the new density in our cryoEM map.

In summary, the register of the mu linker is built from an earlier crystal structure of AP2 (PDB 2VGL). This structure is highly congruent with our pAP2-NECAP cryoEM map (Figure 1---figure supplement 2). Additionally, AP2 has been crystallized many times (PDB 2VGL, PDB 2XA7, PDB 2JKR, PDB 4UQI) and all of these models have an identical register in the mu linker region (residues 159-168). Thus, we are confident in the register of mu starting at residue I159. To build our model of the phosphorylated mu linker, we only had to build Q158 and G157 to reach the critical pT156 residue. We hope we have shown this clearly in our new figure (Figure 1---figure supplement 3). We have also added text to the manuscript to clarify these points and direct readers to the new figure.

Results: "The register leading up to this new density is based on a previous crystal structure (PDB 2VGL), and is confirmed by the positions of several landmark residues near T156 that fit the density well. A detailed schematic for building the critical T156 residue in our model is shown in Figure 1---figure supplement 3."

> My other comments may be harder to address. Given the uncertainty around the modeling of Thr156, their combination of protease accessibility, worm fitness, localization microscopy, and genetic suppressors, altogether, leaves some room for doubt."

We agree that the varying effect of our mutants across our assays is potentially confusing. We have added language in the main text to clarify this point.

Results: "A bona fide interface mutant should reduce the function of NECAP in multiple assays, but not necessarily to the same degree in every assay. This is because each assay exhibits a different linear range, and point mutations may affect *C. elegans* and vertebrate proteins differently."

Results: "It is worth noting that mutation of R112 did not fully suppress the fitness defect, and thus would likely not have been isolated from our genetic screen. Additionally, chemical mutagenesis favors cytosine to thymine DNA transitions, thus disfavoring charge reversal of R112."

> "Finally, the use of 2D cryoEM class averages to support their claim of an induced open state does not convince me. If they have an open state in solution due to interactions with polyanions, they should be able to resolve it in 3D, not just in 2D.\"

3D reconstructions of open AP2 complexes in the presence of DNA oligo are shown in Figure 4---figure supplement 1B. Unfortunately, incubation with DNA causes AP2 complexes to have an extreme preferred orientation in the grid, likely due to exposed hydrophobic regions that interact with the air-water interface. This severely limits the resolution of 3D reconstructions. Nonetheless, we can resolve 3D complexes to 7-10 Å resolution, sufficient to distinguish open and closed complexes.

We have added a new panel to Figure 4---figure supplement 1 which quantifies the 3D classification of complexes into open or closed states and corroborates the results obtained using analysis of 2D classes. The following details were added to the manuscript, and clarifying changes were made to "2D and 3D classification of 'open' versus 'closed' AP2 complexes" in the "Quantification and Statistical Analysis" section.

Results: "Similar values are calculated when 3D classification is used (Figure 4---figure supplement 1C)."

Method details: "After this initial cleaning step, each particle set was randomly split into 10 subsets and subjected to 2D and 3D classification. \[...\] Quantification of particles in the 'open' vs. 'closed' conformation is described in the following section."

Figure 4---figure supplement 1 legend: "(C) Quantification of 3D classification. Four datasets were analyzed and the percentage of particles that classified into open or closed 3D classes were quantified and plotted."

> We would welcome a revised manuscript that addresses these issues and/or clarifies the conclusions so that there is no confusion for readers. We hope you will find these comments constructive, and I include the details to help guide your revision process.

Thank you for including the detailed reviewers comments, which we have found helpful in clarifying and improving our manuscript, especially the Discussion. Below is our response to specific reviewer comments.

We have added a paragraph to the Discussion to better explain our model figure, specifically the open AP2-NECAP complex we propose for which we have not resolved a 3D structure. This complex is poorly behaved in solution, and we have been unable to produce concentrated samples for cryo-EM. In addition, micrographs of grids prepared using low concentration samples have not produced classifiable particles. Nonetheless, we believe there is sufficient evidence to propose this structure and place it early in our model.

Discussion: "The model in Figure 7 depicts NECAP first interacting with an open, unphosphorylated AP2 complex through the NECAP~Ex~ domain. \[...\] A priming interaction of NECAP~Ex~ with activated AP2 is consistent with these observations; initially, NECAP is not competent to inactivate AP2, but is poised to do so later in the cycle, after phosphorylation (Figure 7C)."

We have also added several sentences later in the Discussion to address the unanswered questions of when and where NECAP acts, how NECAP detaches from AP2, and how AP2 becomes dephosphorylated.

Discussion: "The results of this study do not distinguish whether NECAP acts early in endocytosis to promote productive pit formation by limiting aberrant events, or late in the endocytic cycle to uncoat AP2 and allow the complex to initiate new pits. \[...\] It remains to be determined whether NECAP~PHear~ must disengage prior to dephosphorylation, or whether a phosphatase plays a role in NECAP removal from closed complexes."

We clarified our choice of using NECAP2 for our in vitro experiments.

Results: "While there are two paralogues of NECAP in vertebrates, we have previously shown that they function equivalently to bind phosphorylated and open AP2 complexes in vitro and rescue loss of NECAP in *C. elegans* (Beacham et al., 2018). In this work, we use human or mouse NECAP2 for all experiments because of their ease of purification and stability."

We thank the reviewers for pointing us towards reports of inherited NECAP1 mutations associated with human or canine diseases. While these pathogenic mutations in NECAP are exciting, it is difficult to interpret these mutations in the context of this work. The human variants appear to result in loss of NECAP expression, and the missense mutation observed in Giant Schnauzer dogs is outside the PHearEx region of NECAP that we identified as the minimal functional region in our assays and visualized in our cryo-EM structures.

[^1]: These authors contributed equally to this work.
